Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

被引：0
|
作者：
Makoto Ueno
Masafumi Ikeda
Takashi Sasaki
Fumio Nagashima
Nobumasa Mizuno
Satoshi Shimizu
Hiroki Ikezawa
Nozomi Hayata
Ryo Nakajima
Chigusa Morizane
机构：
[1] Kanagawa Cancer Centre Hospital,Department of Hepatobiliary and Pancreatic Oncology
[2] National Cancer Center Hospital East,undefined
[3] Cancer Institute Hospital of JFCR,undefined
[4] Kyorin University,undefined
[5] Aichi Cancer Centre Hospital,undefined
[6] Saitama Cancer Centre,undefined
[7] Eisai Co. Ltd.,undefined
[8] Eisai Inc.,undefined
[9] National Cancer Centre Hospital,undefined
来源：
BMC Cancer | / 20卷
关键词：
Lenvatinib; Biliary tract cancer; Cholangiocarcinoma; Gallbladder cancer; Ampulla of Vater;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] A randomised phase II study of second-line XELIRI regimen versus irinotecan monotherapy in advanced biliary tract cancer patients progressed on gemcitabine and cisplatin
    Yi Zheng
    Xiaoxuan Tu
    Peng Zhao
    Weiqin Jiang
    Lulu Liu
    Zhou Tong
    Hangyu Zhang
    Cong Yan
    Weijia Fang
    Weilin Wang
    British Journal of Cancer, 2018, 119 : 291 - 295
  • [32] Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: Multicenter, multinational study.
    Yi, J.
    Thongprasert, S.
    Doval, D.
    Lee, J.
    Cho, M. N.
    Park, S. H.
    Park, J. O.
    Park, Y. S.
    Kang, W. K.
    Lim, H. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [33] Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp)
    Javle, M. M.
    Oh, D-Y
    Ikeda, M.
    Yong, W-P
    Hsu, K.
    Lindmark, B.
    McIntyre, N.
    Firth, C.
    ESMO OPEN, 2022, 7 (01)
  • [34] Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
    L Fornaro
    S Cereda
    G Aprile
    S Di Girolamo
    D Santini
    N Silvestris
    S Lonardi
    F Leone
    M Milella
    C Vivaldi
    C Belli
    F Bergamo
    S E Lutrino
    R Filippi
    M Russano
    V Vaccaro
    A E Brunetti
    V Rotella
    A Falcone
    M A Barbera
    J Corbelli
    G Fasola
    M Aglietta
    V Zagonel
    M Reni
    E Vasile
    G Brandi
    British Journal of Cancer, 2014, 110 : 2165 - 2169
  • [35] Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer
    Fornaro, L.
    Cereda, S.
    Aprile, G.
    Di Girolamo, S.
    Santini, D.
    Silvestris, N.
    Lonardi, S.
    Leone, F.
    Milella, M.
    Vivaldi, C.
    Belli, C.
    Bergamo, F.
    Lutrino, S. E.
    Filippi, R.
    Russano, M.
    Vaccaro, V.
    Brunetti, A. E.
    Rotella, V.
    Falcone, A.
    Barbera, M. A.
    Corbelli, J.
    Fasola, G.
    Aglietta, M.
    Zagonel, V.
    Reni, M.
    Vasile, E.
    Brandi, G.
    BRITISH JOURNAL OF CANCER, 2014, 110 (09) : 2165 - 2169
  • [36] A phase II study of anlotinib with cediranib as a second-line treatment for patients with advanced biliary tract cancers (aBTCs).
    Zhao, Ruihua
    Zong, Hong
    Jin, Shuiling
    Zhong, Qian
    Jiang, Miao
    Jin, Ming
    Li, Rui
    Jiang, Guozhong
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Sorafenib as second-line treatment option after failure of lenvatinib in patients with unresectable hepatocellular carcinoma
    Tomonari, Tetsu
    Sato, Yasushi
    Tanaka, Hironori
    Tanaka, Takahiro
    Taniguchi, Tatsuya
    Sogabe, Msasahiro
    Okamoto, Koichi
    Miyamoto, Hiroshi
    Muguruma, Naoki
    Takayama, Tetsuji
    JGH OPEN, 2020, 4 (06): : 1135 - 1139
  • [38] Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    Seong Yoon Yi
    Young Suk Park
    Hyo Song Kim
    Hyun Jung Jun
    Kyoung Ha Kim
    Myung Hee Chang
    Min Jae Park
    Ji Eun Uhm
    Jeeyun Lee
    Se Hoon Park
    Joon Oh Park
    Jong Kyun Lee
    Kyu Taek Lee
    Ho Yeong Lim
    Won Ki Kang
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 1141 - 1145
  • [39] Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer
    Park, Y.
    Yi, S.
    Kim, H.
    Lee, S.
    Hwang, I.
    Park, S.
    Park, B.
    Park, J.
    Lim, H.
    Kang, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Benefit of second-line chemotherapy for advanced biliary tract cancer.
    Moik, Florian
    Riedl, Jakob M.
    Winder, Thomas
    Bezan, Angelika
    Rossmann, Christopher
    Szkandera, Joanna
    Kasparek, Anne-Katrin
    Schaberl-Moser, Renate
    Pichler, Martin
    Stoger, Herbert
    Stotz, Michael
    Gerger, Armin
    Posch, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345